Company intelligence / Profile preview
Muna Therapeutics
Copenhagen, Denmarkmunatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Muna Therapeutics has advanced first-in-class small molecule programs targeting neuroinflammation and microglia function. Their lead program includes a TREM2 agonist in IND-enabling studies for early-stage Alzheimer’s disease. The company recently entered a strategic alliance with GSK to leverage its MiND-MAP platform for novel Alzheimer’s drug target identification and validation. No clinical results have been reported yet as the programs are preclinical
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
GSK (strategic alliance for Alzheimer's drug discovery using MiND-MAP platform)Axxam SpA (minority shareholder/target discovery partnership)
Beyond the preview
Go deeper on Muna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Muna Therapeutics.